Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre.

This study shows that the sequential use of biological therapy in IBD does not seem to convey an overall higher risk of serious infections or malignancies, but that underlying more refractory disease seems to increase this risk.